1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
AbbVie Inc.

AbbVie Inc.

ABBV.BA
AbbVie Inc.AR flagBuenos Aires Stock Exchange
40,040.00
ARS
-1,060.00
- -
707.42TMarket Cap
AbbVie Inc.
ABBV.BA
(Buenos Aires Stock Exchange)

Recent

price

40,040.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.68
10.79
11.66
11.84
12.54
14.2
16.1
17.72
22.15
22.49
25.95
31.78
32.81
30.76
31.91
34.6
35.55
Revenue per Share
2.59
2.12
3.34
2.6
1.11
3.2
3.74
3.33
3.85
5.33
2.62
6.53
6.69
2.75
2.42
2.39
2.06
Basic EPS, GAAP
2.8
3.65
3.81
3.64
1.85
4.35
4.12
5.92
8.65
8.64
9.51
12.44
13.71
12.49
10.1
10.08
11.31
Free Cash Flow per Basic Share
- -
- -
- -
1.61
1.67
2.05
2.33
2.58
3.77
4.3
4.37
5.24
5.68
5.97
6.25
6.59
6.69
Dividend per Share
- -
7.4
2.35
1
0.35
1.41
2.76
3.44
2.29
3.2
0.61
1.78
2.71
-0.56
-4.47
-8.75
-10.1
Book Value per Share
3.6
1.81
-3.23
-2.32
-3.54
-17.97
-24.91
-24.02
-30.66
-28.69
-58.3
-52.53
-46.52
-43.89
-51.92
-51.76
-52.66
Tangible Book Value per Share
1,616
1,616
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,769
1,766
1,765
1,768
1,767
Basic Weighted Avg Shares
15,638
17,444
18,380
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
58,054
54,318
56,334
61,160
62,819
Sales/Revenue/Turnover
30.16
20.75
31.65
30.14
17.09
32.97
36.43
33.83
19.49
39.03
24.81
31.89
32.41
24.92
21.11
32.85
33.18
Operating Margin (%)
1,184
1,272
1,150
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,467
8,698
8,386
8,139
8,036
Depreciation Expense
4,178
3,433
5,275
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
11,836
4,863
4,278
4,226
3,635
Net Income, GAAP
13.61
6.41
7.86
22.58
25.12
22.59
24.49
31.29
- -
6.46
- -
11.09
12.11
22.03
- -
35.83
39.06
Effective Tax Rate (%)
26.72
19.68
28.7
21.97
8.89
22.5
23.22
18.82
17.36
23.69
10.08
20.54
20.39
8.95
7.59
6.91
5.79
Profit Margin (%)
4,457
1,457
8,578
10,969
4,688
5,420
6,406
4,582
-294
33,934
-4,488
-7,266
-1,075
-4,839
-13,167
-14,227
-8,571
Working Capital
- -
32
14,630
14,292
10,538
29,240
36,440
30,953
35,002
62,975
77,554
64,189
59,135
52,194
60,340
58,941
64,532
LT Debt
15,703
11,932
3,363
4,492
1,742
3,945
4,636
5,097
-8,446
-8,172
13,097
15,436
17,287
10,397
3,364
-3,228
-6,612
Total Equity
52.42
24.76
34.74
22.93
14.22
22.3
18.3
15.63
- -
26.89
- -
16.66
19.15
14.04
- -
19.13
18.46
Return on Invested Capital (%)
- -
57.19
34.22
24.43
13.16
23.05
17.94
14.51
- -
16.59
- -
16.39
18.64
10.41
- -
10.91
9.36
Return on Capital (%)
- -
57.42
67.33
155.89
166.26
365.34
178.74
107.55
128.33
194.11
158.95
547.27
297.87
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
5,772
8,555
8,326
LT Borrowings
62,971
58,941
64,532
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,767
1,768
1,767
Market Capitalization
45,705
42,392
40,986

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28,539
29,062
33,529
Cash, Cash Equivalents & STI
5,671
5,257
9,391
Accounts Receivable, Net
12,769
12,589
12,479
Inventories
4,938
4,951
5,049
Total Current Liabilities
39,391
43,289
42,100
Payables & Accruals
33,619
34,734
33,774
ST Debt
5,772
8,555
8,326
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-77.54%
-54.72%
-195.96%
Free Cash Flow
11.73%
2.59%
-0.09%
Net Income, GAAP
8.96%
16.09%
-1.22%
Sales/Revenue/Turnover
10.94%
6.37%
8.57%
Total Cash Common Dividend
13.82%
8.75%
5.73%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,310
14,462
14,460
15,102
56,334
2025
13,343
15,423
15,776
16,618
61,160
2026
15,002
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.78
0.78
0.88
-0.01
2.42
2025
0.73
0.53
0.11
1.03
2.39
2026
0.39
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.57
1.56
1.56
1.56
6.25
2025
1.66
1.65
1.65
1.65
6.59
2026
1.75
- -
- -
- -
- -
Similar Companies
Novartis AG (NVS)
Gilead Sciences, Inc. (GILD)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS)
Virbac S.A. (VRBCF)
Merck & Co., Inc. (MRK)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
Business
AbbVie Inc. (ABBV.BA) is a research-driven global biopharmaceutical company that discovers, develops, manufactures and markets innovative medicines and therapies focused on immunology, oncology, neuroscience, eye care, virology, gastroenterology and womens health; its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, Crohns disease and ulcerative colitis; Skyrizi (risankizumab), an interleukin-23 inhibitor for autoimmune conditions; Rinvoq (upadacitinib) for arthritis and other inflammatory diseases; Botox for aesthetics and therapeutic uses; Imbruvica (ibrutinib) for blood cancers; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Venclexta (venetoclax) for leukemia and lymphoma; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, with a robust pipeline including candidates like ABBV-383 for multiple myeloma, Emrelis (Teliso-V) for lung cancer and Vyalev for Parkinsons disease. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company employs approximately 50,000 people worldwide and operates in more than 70 countries, serving millions of patients annually through its commercial scale and external innovation partnerships. Recent developments include the acquisition of Capstan Therapeutics for up to $2.1 billion in June 2025 to advance in vivo CAR-T therapies for autoimmune diseases, fibrosis and cancer; completion of the Capstan deal and earlier acquisitions such as Nimble Therapeutics for $200 million, Aliada Therapeutics for $1.4 billion and Cerevel Therapeutics for $8.7 billion in 2024 to bolster neuroscience and oncology pipelines; partnerships with Neomorph for $1.64 billion on molecular glue degraders and Simcere Zaiming for $1 billion on multiple myeloma treatments in January 2025; a $70 million expansion of biologics manufacturing in Worcester, Massachusetts announced in September 2025; and a $195 million investment in active pharmaceutical ingredient production earlier in 2025, alongside FDA approval of Emrelis in May 2025 and ongoing leadership transition with Robert Michael as CEO since June 2024.